CompletedPhase 2

Efavirenz in Treating Patients With Metastatic Prostate Cancer

France61 participantsStarted 2008-05

Plain-language summary

RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate cancer.

Who can participate

Age range18 Years – 120 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed prostate cancer * Metastatic disease * Castration-refractory disease * No clinical symptoms related to disease progression PATIENT CHARACTERISTICS: * WHO performance status 0-2 PRIOR CONCURRENT THERAPY: * Not specified

What they're measuring

Percentage of Participants Without Prostate-specific Antigen Progression at 3 Months

Timeframe: 3 months

Trial details

NCT IDNCT00964002

SponsorInstitut Bergonié

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-09-19

Results submitted2021-11-25

View on ClinicalTrials.gov More Prostate Cancer trials